



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Placenta as a source of hematopoietic stem cells

**Citation for published version:**

Dzierzak, E & Robin, C 2010, 'Placenta as a source of hematopoietic stem cells', *Trends in Molecular Medicine*, vol. 16, no. 8, pp. 361-7. <https://doi.org/10.1016/j.molmed.2010.05.005>

**Digital Object Identifier (DOI):**

[10.1016/j.molmed.2010.05.005](https://doi.org/10.1016/j.molmed.2010.05.005)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Trends in Molecular Medicine

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



Published in final edited form as:

*Trends Mol Med.* 2010 August ; 16(8): 361–367. doi:10.1016/j.molmed.2010.05.005.

## Placenta as a source of hematopoietic stem cells

**Elaine Dzierzak and Catherine Robin**

Erasmus MC Stem Cell Institute, Dept of Cell Biology, Erasmus University Medical Center  
Rotterdam, Netherlands

### Abstract

The placenta is a large, highly vascularized hematopoietic tissue that functions during embryonic and foetal development of eutherian mammals. Although recognized as the interface tissue important in the exchange of oxygen, nutrients and waste products between the foetus and mother, the placenta has increasingly become a focus of research concerning the ontogeny of the blood system. Here, we describe recent data showing the intrinsic hematopoietic potential and appearance of hematopoietic cells in the mouse and human placenta, and probe the biological rationale behind its hematopoietic function. As a rest tissue that contains potent hematopoietic stem cells, the human placenta could represent (in addition to umbilical cord blood cells) an accessible supplemental source of cells for therapeutic strategies.

### Keywords

human stem cells; placenta; hematopoietic stem cells; NOD-SCID; development

### Early placenta development

The placenta is a mysterious tissue that has been known since the earliest times as the “alter ego” or “external soul” of the foetus. Aristotle recognized it as a tissue from which the embryo receives its nourishment, and Leonardo da Vinci and Vesalius depicted it as a disc at the maternal-foetal interface in the uterus <sup>1</sup>. It was only in the mid-1500s that it gained its name placenta (from Latin), meaning flat cake. Proposed to be the liver and lungs of the foetus, only in 1734 was it established that the foetal and maternal vasculature of the placenta were not continuous <sup>2</sup>. Although this aspect of placental anatomy remained controversial for many years (awaiting improved microscopic techniques and molecular markers), the function of the placenta was accepted to be facilitation of nutrient and waste exchange between the mother and foetus, provision of immunoprotection for the foetus and production of factors and hormones for foetal growth <sup>3</sup>.

The development of the placenta has been extensively studied in the mouse conceptus <sup>4</sup>. At embryonic day (E) 8.5, the allantois, a mesodermal outgrowth from the posterior end of the embryo, contacts the chorionic epithelium in the extraembryonic part of the conceptus (Figure 1A). This event is called chorio-allantoic fusion. Thereafter, a network of vasculature is generated from the allantois and grows into the chorionic plate. These vessels

---

© 2010 Elsevier Ltd. All rights reserved.

Corresponding Author: Elaine Dzierzak, Erasmus MC Stem Cell Institute, Dept of Cell Biology, PO Box 2040, 3000 CA Rotterdam, The Netherlands, Phone: 31 10 704 3172, Fax: 31 10 704 4743, e.dzierzak@erasmusmc.nl.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

undergo extensive branching. The endothelial cells lining these vessels are in direct apposition with syncytiotrophoblasts and it is in the small spaces surrounding these structures that the maternal blood bathes the foetal villi. A diagram of the anatomical structure of the mouse placenta is provided in Figure 1B. Instead of the compact, maze-like villi in the labyrinth layer found in the mouse, the villous structures in the human placenta are less branched and the intervillous space is more open. Placenta architecture varies between species, but there are general similarities across evolution that include placental cell types, functions, and gene and protein expression reflecting developmental and regulatory conservation<sup>5,6</sup>.

The placenta is connected to the embryo through the umbilical cord. The umbilical artery is contiguous with the dorsal aorta, the main artery of the embryo (Figure 2A). Initially the connection is at the caudal aspect of the dorsal aorta, but following vascular remodelling, the connection becomes abdominal<sup>7</sup>. Blood circulation throughout the embryo and extraembryonic tissue is established at E8.25 in the mouse (Figure 2B) and beginning between weeks 3 and 4 of gestation in the human conceptus. Following the development and growth of the placenta at these early stages, maternal circulation flows through the intervillous spaces beginning at approximately E10.5 and about the 11<sup>th</sup> week of gestation in the mouse and human placentas, respectively<sup>8</sup>. It is at this time that the placenta becomes functional in its role as the exchange chamber between mother and foetus.

## The placenta and hematopoiesis

As compared to its generally recognized functions, the appreciation of the placenta as a potent hematopoietic site is relatively recent. Hematopoietic activity was initially observed in the mouse placenta in the 1960s and 1970s, but these findings were not immediately pursued (reviewed in<sup>9</sup>). Studies in human placental villi suggest that already at day 21 postconception, macrophage-like cells and hemangioblastic cords arise from mesenchymal cells<sup>10</sup>. Tissue grafting studies in the avian embryo model by Dieterlen-Lievre reveal that cells derived from the avian allantois contribute to adult haematopoiesis<sup>11</sup>. Subsequent studies by this group established that the mouse placenta harbours a wide range of clonogenic hematopoietic progenitors beginning around E9<sup>12</sup>. Although this is slightly later than the time such cells appear in the embryo proper or the yolk sac (Figure 2B), the placenta contains the most progenitors of any site up until E12 when the foetal liver surpasses it. The continued presence of hematopoietic progenitors in the mouse placenta throughout gestation demonstrates that the placenta is a highly potent hematopoietic site.

Hematopoietic stem cells (HSCs) are found in highly vascularized tissues including the mouse placenta (reviewed in<sup>13-15</sup>). HSCs are the basis of the adult hematopoietic hierarchy that produces all the blood lineages throughout adult life. Putative HSCs are tested by the stringent transplantation assay in which the donor cells are challenged to provide complete, long-term hematopoietic repopulation of adult irradiated (HSC-depleted) normal recipients. Using allelic or transgene markers to distinguish foetal-derived cells, HSCs are detectable in the mouse placenta at early E11 and HSC numbers increase dramatically up to E12.5<sup>16,17</sup>. Thereafter, HSC numbers in the placenta are superseded by the fetal liver, and after E15.5, very few or no HSCs are found in the placenta<sup>16</sup>. Placenta HSCs express many of the same surface marker proteins as adult bone marrow and foetal liver HSCs, including CD34 and c-kit<sup>16</sup>. Also, all placental HSCs express Ly6A (Sca-1) GFP (Stem cell antigen-1, green fluorescent protein)<sup>17</sup>. Interestingly, Ly6A GFP expressing cells localize within the vasculature of the placental labyrinth and the umbilical vessel, and most of these cells express CD34. Histologic analyses show that the midgestation mouse placenta expresses important hematopoietic transcription factors such as Gata-2, Gata-3 and Runx1<sup>17</sup>. Gata-2 is expressed in some endothelial cells and cells surrounding the vessels within the labyrinth,

whereas Gata-3 is restricted to a few cells at the maternal-foetal interface. Runx1 is expressed in cells within the vascular lumen and the endothelium as well as cells surrounding the vasculature of the labyrinth<sup>17, 18</sup>. The patterns of Gata-2 and Runx1 expression strongly suggest HSCs and progenitors are localized within the labyrinth and near the chorionic plate.

## Human placenta hematopoiesis

Throughout development, the human placenta similarly contains a wide variety of hematopoietic cells, as well as mature and immature hematopoietic progenitors and HSCs (Figure 3). Primitive erythroblasts that morphologically resemble those in the yolk sac fill the placental vessels beginning around day 24<sup>19</sup>. These cells express glycophorin-A, GATA-2 and c-KIT, but are not positive for CD34 or CD45. As measured by *in vitro* colonogenic activity, mature and immature hematopoietic progenitors are found as early as week 6 in gestation through week 17, and at term<sup>20-23</sup>. These progenitors are multipotent and produce erythroid and myeloid lineage cells, including granulocytes and macrophages. The progenitors are initially in both CD34<sup>-</sup> and CD34<sup>+</sup> fractions, but by week 15, all progenitors are CD34<sup>+</sup><sup>20-22</sup>. Leukocytes begin to express CD45 at 12-14 weeks in gestation and at term.

As a hematopoietic territory, the appearance of hematopoietic cells in the early gestational stage human placenta is slightly delayed as compared to the other hematopoietic sites (Figure 3). The human yolk sac begins generating blood at day 16 with the production of primitive erythroid cells, and at day 19, the intra-embryonic splanchnopleura (aorta region) becomes hematopoietic. The emergence of multipotent progenitors, HSCs and clusters of cells closely adherent to the ventral wall of the dorsal aorta, starts at around day 27 in the developing splanchnopleura/aorta-gonad-mesonephros (AGM) region<sup>24</sup>. Beginning at day 30 and week 13, the first erythroid progenitors and multilineage progenitors respectively, colonize the liver. Thereafter, the bone marrow becomes hematopoietic<sup>25</sup>. Thus, sequential waves of hematopoietic activity in the human conceptus and placenta are similar to those in the mouse conceptus.

Using the NOD-SCID (non-obese diabetic-severe combined immunodeficient) mouse transplantation assay (the surrogate transplantation assay for human HSC identification), potent multilineage, high-level repopulating HSCs have been found in the human placenta<sup>22</sup>. Donor human placental cells contribute to high percentages of B lymphocytes and myeloid cells in the bone marrow and spleen of NOD-SCID recipients 10 weeks postinjection. HSCs can be found in the human placenta beginning at week 6 of gestation, throughout trimesters 1 and 2, and at the time of delivery (term). Considering the almost total absence of HSCs in the mouse term placenta<sup>16</sup>, the discovery of HSCs in the human term placenta was unexpected. Human placental HSCs were verified as being foetal-derived by human forensic identity PCR analysis, indicating that the human placenta still functions to maintain, expand and/or produce the most immature of foetus-derived hematopoietic cells<sup>22</sup>.

Interestingly, cell extraction methods allowing the isolation of cells from the placenta vasculature reveal that many potent HSCs are either closely adherent to the endothelium or are within the niches of this compartment<sup>22</sup>. At week 6 in gestation, HSCs are found both in the CD34<sup>+</sup> and CD34<sup>-</sup> fractions. It is as yet uncertain whether at later stages of development, placenta HSCs are retained in both these fractions, as they are in umbilical cord blood<sup>26, 27</sup>. If so, the vascular endothelium might be either considered as the cellular source of HSCs or provide an important HSC growth supportive microenvironment.

## Microenvironment of the placenta

Hematopoietic tissues harbour hematopoietic progenitors and stem cells in specific microenvironments or niches<sup>28</sup>. Studies of adult bone marrow show that the microenvironment is a complex structure composed of mesenchymal stromal cells, endothelial cells, osteoblasts, adipocytes, extracellular matrix, growth factors, cytokines and adhesive molecules that provide support and regulatory functions for hematopoietic progenitor or stem-cell homing, self renewal, maintenance and differentiation. A close relationship exists between HSCs and the endosteal and endothelial niches in the bone marrow<sup>29, 30</sup>. The hematopoietic niche of the placenta within the labyrinth is likely to be similar, consisting of endothelial, perivascular and mesenchymal cells but also placenta-specific syncytiotrophoblast cells.

Interestingly, throughout mouse development, the temporal and spatial distribution of mesenchymal stromal cells (MSC) correlates with hematopoietic territories such as the AGM, foetal liver and neonatal bone marrow<sup>31</sup>. MSC lines have been derived from these tissues and many of these cell lines can provide support for hematopoietic cells *in vitro*<sup>32, 33</sup>, underlining the role that stromal cells play in the proliferation and/or survival of HSCs. Such MSCs have osteogenic, adipogenic, chondrogenic, and/or myogenic differentiation potential<sup>34, 35</sup>. Since the mouse placenta is a potent hematopoietic territory it is expected that this tissue will also yield hematopoietic supportive MSC lines and exhibit similar differentiation potentials.

MSC lines have already been isolated from human placenta and amnionic and chorionic fetal membranes (reviewed in<sup>36</sup>). At the developmental stages tested, ranging from week 3 to term, human MSC lines express classical mesenchymal markers as well as markers of pericytes, CD146 and NG2<sup>22, 37</sup>, and after gestational week 6, they possess the typical mesenchymal lineage potentials (osteogenic, adipogenic and/or endothelial)<sup>22, 36-46</sup>. Also, some of these placental MSC lines constitute a potent feeder layer for *in vitro* maintenance and/or expansion of human umbilical cord blood CD34<sup>+</sup> cells and progenitors<sup>22</sup>, primate and human embryonic stem (ES) cells<sup>23, 47, 48</sup>, and long-term-culture-initiating cells<sup>23</sup>. Immunostaining of human placental sections localize such mesenchymal cell types within this tissue. Moreover, localized expression of CD146 and NG2 in the perivascularity of the placenta suggests that placenta mesenchymal cells are pericytes<sup>22, 37</sup>. Interestingly, a MSC line derived [ad1] from the maternal part of a gestation week 3 human placenta provided potent *in vitro* maintenance and expansion of human umbilical cord blood CD34<sup>+</sup> cells and an 8-fold increase in immature hematopoietic progenitors compared to the input number in the sorted CD34<sup>+</sup> cord blood population<sup>22</sup>, suggesting that maternal cells contribute to the early hematopoietic supportive microenvironment by promoting the growth of the placenta as a highly vascular and hematopoietic territory. Thus, the hematopoietic inductive/supportive microenvironment of the placenta could be unique as compared to the other foetal and adult hematopoietic territories, and it most likely consists of the vascular endothelial, mesenchymal and syncytiotrophoblast cells that develop in parallel in the villi.

The coordinated development of microenvironment within the labyrinth requires vessel generation, invasion, branching morphogenesis and syncytiotrophoblast differentiation<sup>4</sup>. Genetic studies in mutant mice have identified a panel of genes important for some of these processes<sup>5</sup>. For example, the transcription factor encoded by *Gcm1* is a pivotal molecule in the initiation of morphogenesis and syncytiotrophoblast differentiation. The germline deletion of *Gcm1* (Glial cells missing 1) in mice is lethal at midgestation owing to a failure to develop the placenta labyrinth layer<sup>49</sup>. Originally identified in *Drosophila*, *Gcm* is involved in macrophage-like cell development<sup>50</sup>. In the mouse it is almost exclusively expressed in the placenta<sup>51</sup>. Similarly, deletion of *Esx1*, a homeobox gene, results in failure

to develop the labyrinth layer<sup>52</sup>. *PPAR* $\gamma$  is required for the invasion of foetal vessels into the presumptive labyrinth at E9.5, as are the developmental factors such *Wnt2* and *EphB4/ephrin B2*<sup>4</sup>. It will be interesting to determine how the placental hematopoietic microenvironment and hematopoiesis are affected in these mouse models, and whether hematopoiesis occurs normally in other hematopoietic sites.

### Generator or storage tissue for hematopoietic cells?

The hematopoietic system originates in the mesodermal germ layer of the conceptus. Histologic observation of yolk sac blood island anatomy linked the development of vascular endothelial and hematopoietic cells<sup>53,54</sup>. These studies suggested a common mesodermal precursor for these two lineages of cells, and the precursor cell was given the name hemangioblast. Other histologic studies proposed that the precursors of hematopoietic cells in the embryonic dorsal aorta are hemogenic endothelial cells, as clusters of hematopoietic cells are closely associated with the ventral endothelium of the dorsal aorta at early stages of development<sup>13</sup>. Cell tracing<sup>55,56</sup> in mouse models in conjunction with vital imaging of mouse ES cell hematopoietic differentiation cultures and *in vitro* cultured early posterior primitive streak cells<sup>57,58</sup> show that hematopoietic cells transit through an endothelial cell stage before taking on hematopoietic fate. *In vivo* real-time imaging of the intact midgestational dorsal aorta shows the emergence of hematopoietic progenitor/stem cells from endothelial cells lining this vessel<sup>59</sup>. Because the vasculature and other cells of the placenta originate from the allantoic mesoderm, which arises from the primitive streak at early stages of development, the allantoic mesoderm is postulated to be hemogenic.

Indeed, the allantois of the developing chick can produce hematopoietic cells<sup>11,60</sup>. Blood-island-like clusters of hematopoietic cells are found in the prevascularized allantois, and upon engraftment into the coelom of host embryos, the cells arising from the donor allantois contribute to adult blood. Results in mouse embryo grafting experiments examining this question are less clear. After engraftment and a short culture period, donor allantoic cells contribute to the endothelial lineage but only very rarely to a small number of erythroid cells<sup>61</sup>. More recently, others have found that the mouse prefusion allantois and chorion tissues both possess intrinsic hematopoietic potential<sup>62,63</sup>; they give rise to clonogenic haematopoietic progenitors following a 48-hour organ explant culture period<sup>63</sup>. Moreover, definitive hematopoietic markers such as *Runx1* (a pivotal hematopoietic transcription factor<sup>64</sup>) and *Ly6A GFP* (HSC marker<sup>65</sup>) are expressed in the early allantois and chorion, indicating the hematopoietic potential<sup>63</sup>. Thus, before it becomes vascularized, the early stage placenta is intrinsically hemogenic.

At a slightly later developmental stage, the mouse placenta generates hematopoietic progenitors. Embryos deficient for the *Ncx1* gene<sup>66</sup> lack a heart beat and blood circulation, which is normally established between the embryo body and the extraembryonic tissues at E8.25. If in the absence of circulation a tissue such as the yolk sac, placenta or the body of the embryo contains hematopoietic cells, then the hematopoietic cells must be generated intrinsically<sup>67</sup>. Indeed, erythro-myeloid and lymphoid progenitors are detected in the *Ncx1*<sup>-/-</sup> embryo body, yolk sac and placenta<sup>18,67</sup>, indicating their intrinsic hemogenic/hematopoietic capacity.

Because *Ncx1*<sup>-/-</sup> embryos die before E11, the time at which HSC activity is first detected in the placenta, it is as yet uncertain whether the placenta can generate HSCs. Quantitative studies, in which HSC numbers in each of the tissues of the conceptus was determined<sup>68</sup>, suggest that the aorta (the only tissue shown to autonomously generate HSCs) cannot produce all of the HSCs that eventually are found in the foetal liver and the adult bone marrow (tissues that harbour but do not generate HSCs) (Figure 2). In this regard, the



midgestation mouse placenta contains an abundance of HSCs<sup>16,17</sup>, supporting the notion that this highly vascularized tissue generates HSCs from hemogenic endothelium and/or that it provides a unique supportive growth niche for expansion of aorta-derived HSCs. Similarly, the human placenta might also autonomously generate HSCs and/or promote their expansion to large numbers before they migrate to the bone marrow. Recent studies showing the importance of mechanical stimuli provided by circulation in AGM HSC development<sup>69</sup> suggests that mechanical stimuli as well as hypoxia<sup>70</sup> could be important factors in placental and HSC development.

## The placenta in hematopoietic development

Hematopoiesis in the mouse and human conceptus progresses in wave-like stages (reviewed in<sup>13,25</sup>). The three hemogenic/hematopoietic tissues, the yolk sac (YS), the AGM region (and its precursor tissue the para-aortic splanchnopleura) and the chorio-allantoic placenta are active at different but overlapping stages of development. They produce varying repertoires and quantities of hematopoietic cells and support them in distinct microenvironments. It is curious that eutherian mammals use the placenta as a hemogenic and hematopoietic tissue, whereas other mammals and nonmammalian vertebrates develop a fully functional hematopoietic system in the absence of a placenta. However, in these other vertebrate embryos, it is possible that hematopoietic cells emerging in the allantois are amplified elsewhere. In marsupials, the allantois is mainly avascular and does not fuse with the chorion. Many variations in placental structure are seen in mammals. It is discoid in mouse and man, and in species like the pig, horse and whale it is diffuse and distributed over most of the uterus inner surface<sup>4</sup>. Interestingly, the evolution of the placenta as a complex organ has occurred multiple times, as found in the fish genus *Poeciliopsis*<sup>71</sup>. Hence, is the more fully developed placenta irrelevant as a hematopoietic tissue or does it play a special role in blood development in mammals?

One notion is that the large size of the mammalian foetus and the extended length of the gestational period might require a greater quantity of hematopoietic progenitors and HSCs for foetal growth, and this can only be accomplished in an extra hematopoietic tissue such as the placenta. Indeed, the placenta is large as compared to the size of the other hematopoietic tissues of the embryo, and thus, it represents a significant space for producing, amplifying and/or harbouring hematopoietic cells.

Another idea concerning the functional relevance of the placenta comes from studies of *Runx1* haploinsufficient mouse embryos; in these mice, which have half a dose of the Runx1 transcription factor protein, the AGM region produces fewer HSCs<sup>43,72</sup>. However, *Runx1* haploinsufficiency does not have negative effects on HSCs in the extraembryonic tissues (yolk sac and placenta) or fetal liver, and instead results in a surprising increase in HSC numbers in the placenta<sup>43</sup>. Hence, the placenta appears to be more resistant to genetic/physiologic changes, implicating it as a highly robust hematopoietic tissue in nonhomeostatic conditions.

Additionally, the provision of growth factors such as interleukin 3 (IL-3) by the maternal part of the placenta can stimulate the hematopoiesis<sup>73</sup>. IL-3 is a potent HSC survival and proliferation factor during embryonic development<sup>43</sup> and the *IL-3* gene is a known direct downstream transcriptional target of Runx1. Interestingly, human placenta MSCs produce SCF (stem cell factor), Flt3 ligand, IL-6 and M-CSF (macrophage-colony stimulating factor), among other hematopoietic factors<sup>23</sup>. Thus, both maternal- and foetal-derived factors may contribute to the growth of the placenta hematopoietic niche and the support of hematopoietic cells.

Overall, the human placenta plays an important and multifaceted role in the development and growth of the foetus. Its structural complexity and its immense vascular network containing large quantities of circulating blood cells and progenitors, make it a difficult tissue to understand, particularly concerning its precise role in the development of the mammalian hematopoietic system. The ongoing challenge is to determine whether the placenta just contains reserve cohorts of hematopoietic progenitor and stem cells, or whether these cohorts of cells are required for adult hematopoiesis and migrate to the bone marrow at the end of fetal development before the time of delivery.

## Concluding remarks

The discovery of HSCs in the human placenta throughout development and their localization to the highly vascular compartment of this tissue opens new lines of inquiry with potential medical implications (Box 1). As a new source of HSCs, the term human placenta as yet yields only relatively small numbers. The present cell extraction procedures that include dissection, enzymatic digestion with three enzymes (collagenase, dispase and pancreatin) and mechanical dispersion yield about 10% of the total number of HSCs found in a unit of umbilical cord blood<sup>22, 74</sup>. Although placenta HSCs can be stored much like umbilical cord blood HSCs, harvest efficiencies together with the cost- and labor-effectiveness must improve before any potential clinical applications can be considered. In this regard, a more easily isolatable source of HSCs with potential for regenerative medicine has recently been discovered, the amniotic fluid<sup>75</sup>.

### Box 1

#### Outstanding Questions

*Does the placenta have the ability to generate hematopoietic stem cells?* The placenta contains hematopoietic stem cells<sup>22</sup>, but it is as yet undetermined whether the placenta can intrinsically produce these potent, therapeutically important stem cells<sup>18</sup>.

*Does the placenta contain hemangioblasts and/or hemogenic endothelial cells?* Results from studies of the mouse chorion and allantois have shown that these tissues possess intrinsic hematopoietic potential<sup>62, 63</sup>. In the absence of circulation, the mouse placenta intrinsically generates multipotent progenitors<sup>18</sup>; however, it is as yet unknown whether the vasculature of the labyrinth and/or the mesenchymal cells within the villi are hemogenic.

*How many hematopoietic stem cells does a human placenta contain?* If placenta-derived cells are to be contemplated for hematopoietic transplantation purposes, they must be at least as abundant as those available in the umbilical cord blood. Improvements in extraction procedures should optimize both quantitative yields and viability of these cells.

*How robust are placenta HSCs in transplantation scenarios?* Xenotransplants of human placenta cells reveal the presence of multipotent, long-term engrafting HSCs. However, it is uncertain whether placental HSCs are qualitatively as potent (in proliferation, differentiation and self-renewal) as those from umbilical cord blood and adult bone marrow.

*Does the placenta contain a unique hematopoietic inductive/supportive microenvironment?* The placenta is an extraembryonic and transient tissue; it is uncertain whether unique placental cell types and genetic programs regulate the development of hematopoietic cells differently than in the other embryonic and adult hematopoietic tissues.



Importantly, knowledge from developmental studies demonstrating the hemogenic nature of the early-stage chorio-allantoic placenta<sup>18, 62, 63</sup> offers a new and exciting challenge in the field. Insights into the signals that drive hematopoietic cell generation from mesodermal precursors, endothelial cells and the development of placenta labyrinth and villi could provide new strategies for the production of hematopoietic cells from the numerous vascular endothelial cells of the foetal part of this tissue. A recent study with early stage human embryos has identified a marker ACE (angiotensin converting enzyme, CD143) recognized by the BB9 antibody, on a subset of human mesoderm that establishes a population of hemogenic endothelial cells within the fetus<sup>76</sup>. The ACE-expressing cells possess hematopoietic potential in long term cultures and in SCID mouse *in vivo* reconstitution assays. Moreover, ACE-expressing cells isolated from human ES cells differentiated into embryoid bodies are hemangioblastic-like angiohematopoietic cells. It will be interesting to examine the human placenta for BB9 expression and if such cells are found to examine their hemogenic potential. Characterization of the molecular program of ACE-expressing cells should yield information on the genes involved in HSC specification, amplification and maintenance.

Of future interest is the prospect of using this knowledge of the genetic program to induce the differentiation of early populations of hemogenic cells to HSC fate, particularly if large numbers of such cells can be isolated from the placenta. Alternatively, with the advancement of the technology of reprogramming somatic cells to pluripotent stem cells, it may be possible, with our complete knowledge of the pivotal factors involved in HSC generation to obtain other patient-specific cells that can be reprogrammed into therapeutically potent HSCs<sup>77</sup>. In this regard, the human placenta, allantoic and chorionic foetal membranes<sup>36</sup> provide an abundant source of developmentally young somatic cells such as MSCs, that may be stored, differentiated and/or reprogrammed for regenerative medicine.

## Acknowledgments

The authors thank lab members and particularly K. Bollerot, S. Mendes, E. Haak, M. Crisan, F. Cerisoli, I. Lauw, P. Kaimakis, R. Jorna, P. Imanirad, R. van der Linden, E. Steegers and T. Cupedo who contributed to these studies. We also thank Mihaela Crisan for critical reading of the manuscript. Support was provided by the Landsteiner Society for Blood Research (0614), NIH R37 (DK51077), Dutch BSIK Stem Cells in Development and Disease (03038) and NWO VIDI (917.76.345).

## References

1. Longo LD, Reynolds LP. Some historical aspects of understanding placental development, structure and function. *Int J Dev Biol.* 2010; 54:237–255. [PubMed: 19876830]
2. Pijnenborg R, Vercruyse L. Erasmus Darwin's enlightened views on placental function. *Placenta.* 2007; 28:775–778. [PubMed: 17481727]
3. Gude NM, et al. Growth and function of the normal human placenta. *Thromb Res.* 2004; 114:397–407. [PubMed: 15507270]
4. Rossant, J.; Cross, JC. Lineage Specification and Differentiation: Extraembryonic Lineages. In: Rossant, J.; Tam, PL., editors. *Mouse development: patterning, morphogenesis and organogenesis.* Academic Press; 2001. p. 155-174.
5. Cross JC, et al. Genes, development and evolution of the placenta. *Placenta.* 2003; 24:123–130. [PubMed: 12596737]
6. Rawn SM, Cross JC. The evolution, regulation, and function of placenta-specific genes. *Annu Rev Cell Dev Biol.* 2008; 24:159–181. [PubMed: 18616428]
7. Garcia-Porrero JA, et al. Potential intraembryonic hemogenic sites at pre-liver stages in the mouse. *Anat Embryol (Berl).* 1995; 192:425–435. [PubMed: 8546334]
8. Georgiades P, et al. Comparative developmental anatomy of the murine and human definitive placentae. *Placenta.* 2002; 23:3–19. [PubMed: 11869088]

9. Mikkola HK, et al. Placenta as a site for hematopoietic stem cell development. *Exp Hematol.* 2005; 33:1048–1054. [PubMed: 16140153]
10. Demir R, et al. Fetal vasculogenesis and angiogenesis in human placental villi. *Acta Anat (Basel).* 1989; 136:190–203. [PubMed: 2481376]
11. Caprioli A, et al. Blood-borne seeding by hematopoietic and endothelial precursors from the allantois. *Proc Natl Acad Sci U S A.* 1998; 95:1641–1646. [PubMed: 9465069]
12. Alvarez-Silva M, et al. Mouse placenta is a major hematopoietic organ. *Development (Cambridge, England).* 2003; 130:5437–5444.
13. Dzierzak E, Speck NA. Of lineage and legacy: the development of mammalian hematopoietic stem cells. *Nat Immunol.* 2008; 9:129–136. [PubMed: 18204427]
14. Ottersbach K, Dzierzak E. The placenta as a haematopoietic organ. *Int J Dev Biol.* 2010; 54
15. Gekas C, et al. Isolation and visualization of mouse placental hematopoietic stem cells. *Current protocols in stem cell biology.* 2008; Chapter 2(Unit 2A 8 1-2A 8 14)
16. Gekas C, et al. The placenta is a niche for hematopoietic stem cells. *Dev Cell.* 2005; 8:365–375. [PubMed: 15737932]
17. Ottersbach K, Dzierzak E. The murine placenta contains hematopoietic stem cells within the vascular labyrinth region. *Dev Cell.* 2005; 8:377–387. [PubMed: 15737933]
18. Rhodes KE, et al. The emergence of hematopoietic stem cells is initiated in the placental vasculature in the absence of circulation. *Cell Stem Cell.* 2008; 2:252–263. [PubMed: 18371450]
19. Challier JC, et al. Immunocytological evidence for hematopoiesis in the early human placenta. *Placenta.* 2005; 26:282–288. [PubMed: 15823614]
20. Barcena A, et al. The human placenta is a hematopoietic organ during the embryonic and fetal periods of development. *Dev Biol.* 2009; 327:24–33. [PubMed: 19073167]
21. Barcena A, et al. A new role for the human placenta as a hematopoietic site throughout gestation. *Reprod Sci.* 2009; 16:178–187. [PubMed: 19208786]
22. Robin C, et al. Human placenta is a potent hematopoietic niche containing hematopoietic stem and progenitor cells throughout development. *Cell Stem Cell.* 2009; 5:385–395. [PubMed: 19796619]
23. Zhang Y, et al. Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. *Exp Hematol.* 2004; 32:657–664. [PubMed: 15246162]
24. Tavian M, et al. The human embryo, but not its yolk sac, generates lympho-myeloid stem cells: mapping multipotent hematopoietic cell fate in intraembryonic mesoderm. *Immunity.* 2001; 15:487–495. [PubMed: 11567638]
25. Tavian M, Peault B. Embryonic development of the human hematopoietic system. *Int J Dev Biol.* 2005; 49:243–250. [PubMed: 15906238]
26. Bhatia M, et al. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. *Nat Med.* 1998; 4:1038–1045. [PubMed: 9734397]
27. Wang J, et al. SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. *Blood.* 2003; 101:2924–2931. [PubMed: 12480697]
28. Yaniv I, et al. The tale of early hematopoietic cell seeding in the bone marrow niche. *Stem Cells Dev.* 2006; 15:4–16. [PubMed: 16522158]
29. Calvi LM, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature.* 2003; 425:841–846. [PubMed: 14574413]
30. Lo Celso C, et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. *Nature.* 2009; 457:92–96. [PubMed: 19052546]
31. Mendes SC, et al. Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny. *Development (Cambridge, England).* 2005; 132:1127–1136.
32. Moore KA, et al. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. *Blood.* 1997; 89:4337–4347. [PubMed: 9192756]
33. Oostendorp RA, et al. Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. *Blood.* 2002; 99:1183–1189. [PubMed: 11830464]


34. Durand C, et al. Mesenchymal lineage potentials of aorta-gonad-mesonephros stromal clones. *Haematologica*. 2006; 91:1172–1179. [PubMed: 16956815]
35. Zipori D. Mesenchymal stem cells: harnessing cell plasticity to tissue and organ repair. *Blood Cells Mol Dis*. 2004; 33:211–215. [PubMed: 15528133]
36. Parolini O, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. *Stem Cells*. 2008; 26:300–311. [PubMed: 17975221]
37. Crisan M, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell*. 2008; 3:301–313. [PubMed: 18786417]
38. Fukuchi Y, et al. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. *Stem Cells*. 2004; 22:649–658. [PubMed: 15342929]
39. Igura K, et al. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. *Cytotherapy*. 2004; 6:543–553. [PubMed: 15770794]
40. Li CD, et al. Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. *Cell research*. 2005; 15:539–547. [PubMed: 16045817]
41. Miao Z, et al. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. *Cell Biol Int*. 2006; 30:681–687. [PubMed: 16870478]
42. Portmann-Lanz CB, et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. *Am J Obstet Gynecol*. 2006; 194:664–673. [PubMed: 16522395]
43. Robin C, et al. An unexpected role for IL-3 in the embryonic development of hematopoietic stem cells. *Dev Cell*. 2006; 11:171–180. [PubMed: 16890157]
44. Wulf GG, et al. Mesengenic progenitor cells derived from human placenta. *Tissue Eng*. 2004; 10:1136–1147. [PubMed: 15363170]
45. Yen BL, et al. Isolation of multipotent cells from human term placenta. *Stem Cells*. 2005; 23:3–9. [PubMed: 15625118]
46. Zhang X, et al. Mesenchymal progenitor cells derived from chorionic villi of human placenta for cartilage tissue engineering. *Biochem Biophys Res Commun*. 2006; 340:944–952. [PubMed: 16403457]
47. Kim SJ, et al. Human placenta-derived feeders support prolonged undifferentiated propagation of a human embryonic stem cell line, SNUhES3: comparison with human bone marrow-derived feeders. *Stem Cells Dev*. 2007; 16:421–428. [PubMed: 17610372]
48. Miyamoto K, et al. Human placenta feeder layers support undifferentiated growth of primate embryonic stem cells. *Stem Cells*. 2004; 22:433–440. [PubMed: 15277690]
49. Anson-Cartwright L, et al. The glial cells missing-1 protein is essential for branching morphogenesis in the chorioallantoic placenta. *Nature genetics*. 2000; 25:311–314. [PubMed: 10888880]
50. Lebestky T, et al. Specification of *Drosophila* hematopoietic lineage by conserved transcription factors. *Science (New York, N Y)*. 2000; 288:146–149.
51. Basyuk E, et al. Murine *Gcm1* gene is expressed in a subset of placental trophoblast cells. *Dev Dyn*. 1999; 214:303–311. [PubMed: 10213386]
52. Li Y, Behringer RR. *Esx1* is an X-chromosome-imprinted regulator of placental development and fetal growth. *Nature genetics*. 1998; 20:309–311. [PubMed: 9806555]
53. Murray P. The development in vitro of the blood of the early chick embryo. *Proc Roy Soc London*. 1932; 11:497–521.
54. Sabin F. Studies on the origin of blood vessels and of red blood corpuscles as seen in the living blastoderm of chicks during the second day of incubation. *Carnegie Inst Wash Pub # 272, Contrib Embryol*. 1920; 9:214.
55. Chen MJ, et al. *Runx1* is required for the endothelial to haematopoietic cell transition but not thereafter. *Nature*. 2009; 457:887–891. [PubMed: 19129762]
56. Zovein AC, et al. Fate tracing reveals the endothelial origin of hematopoietic stem cells. *Cell Stem Cell*. 2008; 3:625–636. [PubMed: 19041779]
57. Eilken HM, et al. Continuous single-cell imaging of blood generation from haemogenic endothelium. *Nature*. 2009; 457:896–900. [PubMed: 19212410]

58. Lancrin C, et al. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. *Nature*. 2009; 457:892–895. [PubMed: 19182774]
59. Boisset JC, et al. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. *Nature*. 2010; 464:116–120. [PubMed: 20154729]
60. Caprioli A, et al. Hemangioblast commitment in the avian allantois: cellular and molecular aspects. *Dev Biol*. 2001; 238:64–78. [PubMed: 11783994]
61. Downs KM, et al. Vascularization in the murine allantois occurs by vasculogenesis without accompanying erythropoiesis. *Development (Cambridge, England)*. 1998; 125:4507–4520.
62. Corbel C, et al. Hematopoietic potential of the pre-fusion allantois. *Dev Biol*. 2007; 301:478–488. [PubMed: 17010964]
63. Zeigler BM, et al. The allantois and chorion, when isolated before circulation or chorio-allantoic fusion, have hematopoietic potential. *Development (Cambridge, England)*. 2006; 133:4183–4192.
64. North TE, et al. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. *Immunity*. 2002; 16:661–672. [PubMed: 12049718]
65. de Bruijn MF, et al. Hematopoietic stem cells localize to the endothelial cell layer in the midgestation mouse aorta. *Immunity*. 2002; 16:673–683. [PubMed: 12049719]
66. Koushik SV, et al. Targeted inactivation of the sodium-calcium exchanger (Ncx1) results in the lack of a heartbeat and abnormal myofibrillar organization. *Faseb J*. 2001; 15:1209–1211. [PubMed: 11344090]
67. Lux CT, et al. All primitive and definitive hematopoietic progenitor cells emerging before E10 in the mouse embryo are products of the yolk sac. *Blood*. 2008; 111:3435–3438. [PubMed: 17932251]
68. Kumaravelu P, et al. Quantitative developmental anatomy of definitive haematopoietic stem cells/long-term repopulating units (HSC/RUs): role of the aorta-gonad-mesonephros (AGM) region and the yolk sac in colonisation of the mouse embryonic liver. *Development (Cambridge, England)*. 2002; 129:4891–4899.
69. North TE, et al. Hematopoietic stem cell development is dependent on blood flow. *Cell*. 2009; 137:736–748. [PubMed: 19450519]
70. Dunwoodie SL. The role of hypoxia in development of the Mammalian embryo. *Dev Cell*. 2009; 17:755–773. [PubMed: 20059947]
71. Reznick DN, et al. Independent origins and rapid evolution of the placenta in the fish genus *Poeciliopsis*. *Science (New York, N Y)*. 2002; 298:1018–1020.
72. Cai Z, et al. Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. *Immunity*. 2000; 13:423–431. [PubMed: 11070161]
73. Chamley LW, et al. Is interleukin-3 important in antiphospholipid antibody-mediated pregnancy failure? *Fertil Steril*. 2001; 76:700–706. [PubMed: 11591401]
74. Bhatia M, et al. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. *Proc Natl Acad Sci U S A*. 1997; 94:5320–5325. [PubMed: 9144235]
75. Ditadi A, et al. Human and murine amniotic fluid c-Kit+Lin- cells display hematopoietic activity. *Blood*. 2009; 113:3953–3960. [PubMed: 19221036]
76. Zambidis ET, et al. Emergence of human angiohematopoietic cells in normal development and from cultured embryonic stem cells. *Annals of the New York Academy of Sciences*. 2007; 1106:223–232. [PubMed: 17360801]
77. Graf T, Enver T. Forcing cells to change lineages. *Nature*. 2009; 462:587–594. [PubMed: 19956253]

## Glossary

<b>Placenta</b>	extraembryonic tissue derived from the chorion and allantois of the early stage mammalian conceptus.
-----------------	--


<b>Allantois</b>	posterior outgrowth of the early stage embryo with hematopoietic potential. It gives rise to the vessels in the umbilical cord of mammals. In birds and reptiles, it is involved in oxygen exchange and is a reservoir of nitrogenous waste.
<b>Chorion</b>	membrane separating the fetus and mother that is formed by the extraembryonic mesoderm and trophoblast.
<b>Endosteal and endothelial niches</b>	specific anatomical locations/microenvironments within the adult bone marrow that produce factors or provide important cell-cell interactions for the maintenance, self-renewal and/or differentiation of hematopoietic progenitors and stem cells. The endosteal niche containing osteoblasts juxtaposed to the bone. The endothelial niche is the vasculature within the bone marrow.
<b>Hematopoietic stem cells</b>	the rare cells existing within the bone marrow cavities of the adult that contribute to the life-long production of all blood cells of the hematopoietic system. These cells are long-lived, self renewing and possess potential to produce all hematopoietic cell lineages.
<b>Hematopoietic progenitor cells</b>	intermediate cells within the adult hematopoietic cell differentiation hierarchy. Having restricted differentiation potential, they expand and differentiate to one or a few hematopoietic lineages. They are generally short-lived and do not self-renew.
<b>Hemangioblastic cords</b>	In the early stage human placenta, mesodermal/mesenchymal cells that are the precursors of vascular endothelial and hematopoietic cells.
<b>Labyrinth</b>	region of the placenta in which the trophoblast and its associated fetal blood vasculature undergoes extensive branching of the villi into a densely packed structure.
<b>Pericytes</b>	a relatively undifferentiated cell type that surrounds blood vessels. It possesses multilineage differentiation potential and is thought to be the precursor of mesenchymal stem/stromal cells (MSC).
<b>Syncytiotrophoblasts</b>	the outer most cell type of the fetal placenta. They invade the uterine wall and provide the large surface area for exchange of oxygen, nutrients and waste between the fetus and mother.




**Figure 1.**

Placenta structure at different times in development (a) Early stages of chorio-allantoic placenta formation. The placenta is formed from the fusion of the allantois with the chorion. The allantois is a mesodermal outgrowth emanating from the posterior primitive streak. It elongates and upon contact with the chorionic mesoderm gives rise to the labyrinth of the placenta. (b) Mouse placenta structure. The placenta consists of the several cell types and layers. The side of the placenta facing the fetus is the labyrinth. It consists of a vascular network contiguous with the umbilical cord. The network of vessels in the labyrinth form branched villous structures that are surrounded by mesenchymal stromal and syncytiotrophoblast cells. The maternal vessels run through the spongiotrophoblast region (facing the mother) to open into the intervillous space (white area) where physiologic exchange between mother and fetus occurs.





**Figure 2.** Hematopoiesis in the mouse embryo and placenta. (a) Sites of hematopoiesis in the midgestation (E10.5) mouse conceptus. Extraembryonic hematopoietic territories include the chorio-allantoic placenta and the yolk sac. Hematopoietic territories within the embryo body are the aorta (hematopoietic part of the AGM region) and the liver. The yolk sac, placenta and AGM are sites of *de novo* hematopoietic cell generation, whereas the liver is colonized by exogenously generated hematopoietic cells. Temporal appearance of hematopoietic cells in different tissues (from E 7.5 until birth).



**Figure 3.** Hematopoiesis in the human conceptus and placenta. Temporal appearance of hematopoietic cells in the yolk sac (YS), AGM region, liver and placenta of the human conceptus from gestational weeks in the first and second trimesters through term. BFU-E (burst forming unit-erythroid) represents the earliest erythroid progenitors. Multipotent progenitors can produce erythroid and myeloid lineage cells.